{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:42:43Z","timestamp":1790613763388,"version":"4.1.0"},"publisher-location":"Cham","reference-count":247,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030712013","type":"print"},{"value":"9783030712020","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/5584_2020_604","type":"book-chapter","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T16:10:47Z","timestamp":1608135047000},"page":"115-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review"],"prefix":"10.1007","author":[{"given":"Evangelista","family":"Sagnelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Sagnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariantonietta","family":"Pisaturo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Camaioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Astorri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"issue":"12","key":"604_CR1","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1002\/jmv.24897","volume":"89","author":"S Abdel Alem","year":"2017","unstructured":"Abdel Alem S, Elsharkawy A, Fouad et al (2017) Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: single center experience. J Med Virol 89(12):2181\u20132187. https:\/\/doi.org\/10.1002\/jmv.24897","journal-title":"J Med Virol"},{"issue":"7","key":"604_CR2","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/jgh.14067","volume":"33","author":"LE Adinolfi","year":"2018","unstructured":"Adinolfi LE, Nevola R, Guerrera B et al (2018a) Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol 33(7):1379\u20131382. https:\/\/doi.org\/10.1111\/jgh.14067","journal-title":"J Gastroenterol Hepatol"},{"issue":"41","key":"604_CR3","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.3748\/wjg.v24.i41.4617","volume":"24","author":"LE Adinolfi","year":"2018","unstructured":"Adinolfi LE, Rinaldi L, Nevola R (2018b) Chronic hepatitis C, atherosclerosis and cardiovascular disease: what impact of direct-acting antiviral treatments? World J Gastroenterol 24(41):4617\u20134621. https:\/\/doi.org\/10.3748\/wjg.v24.i41.4617","journal-title":"World J Gastroenterol"},{"issue":"8","key":"604_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/14787210.2018.1505500","volume":"16","author":"LE Adinolfi","year":"2018","unstructured":"Adinolfi LE, Rinaldi L, Marrone A et al (2018c) The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C. Expert Rev Anti-Infect Ther 16(8):595\u2013597. https:\/\/doi.org\/10.1080\/14787210.2018.1505500","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"604_CR5","doi-asserted-by":"publisher","unstructured":"Alessio L, Onorato L, Sangiovanni V et al (2020) DAA-based treatment for HIV-HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study. Antivir Ther. https:\/\/doi.org\/10.3851\/IMP3353","DOI":"10.3851\/IMP3353"},{"issue":"Suppl 1","key":"604_CR6","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/s1590-8658(07)80015-6","volume":"39","author":"A Alisi","year":"2007","unstructured":"Alisi A, Giannini C, Spaziani A et al (2007) Hepatitis C virus core protein enhances B lymphocyte proliferation. Dig Liver Dis 39(Suppl 1):S72\u2013S75. https:\/\/doi.org\/10.1016\/s1590-8658(07)80015-6","journal-title":"Dig Liver Dis"},{"issue":"10","key":"604_CR7","doi-asserted-by":"publisher","first-page":"e0162965","DOI":"10.1371\/journal.pone.0162965","volume":"11","author":"L Alric","year":"2016","unstructured":"Alric L, Besson C, Lapidus N et al (2016) Antiviral treatment of HCV-infected patients with B-cell non-Hodgkin lymphoma: ANRS HC-13 Lympho-C study. PLoS One 11(10):e0162965. https:\/\/doi.org\/10.1371\/journal.pone.0162965","journal-title":"PLoS One"},{"issue":"1","key":"604_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2000-9505","volume":"20","author":"HJ Alter","year":"2000","unstructured":"Alter HJ, Seeff LB (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20(1):17\u201335. https:\/\/doi.org\/10.1055\/s-2000-9505","journal-title":"Semin Liver Dis"},{"issue":"27","key":"604_CR9","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJM199212313272702","volume":"327","author":"MJ Alter","year":"1992","unstructured":"Alter MJ, Margolis HS, Krawczynski K et al (1992) The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B hepatitis study team. N Engl J Med 327(27):1899\u20131905. https:\/\/doi.org\/10.1056\/NEJM199212313272702","journal-title":"N Engl J Med"},{"issue":"6","key":"604_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/jvh.12867","volume":"25","author":"MJ \u00c1lvarez-Ossorio","year":"2018","unstructured":"\u00c1lvarez-Ossorio MJ, Sarmento E, Castro R, Granados R et al (2018) Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort. J Viral Hepat 25(6):699\u2013706. https:\/\/doi.org\/10.1111\/jvh.12867","journal-title":"J Viral Hepat"},{"issue":"12","key":"604_CR11","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1253\/circj.cj-08-0459","volume":"72","author":"O Alyan","year":"2008","unstructured":"Alyan O, Kacmaz F, Ozdemir O et al (2008) Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J 72(12):1960\u20131965. https:\/\/doi.org\/10.1253\/circj.cj-08-0459","journal-title":"Circ J"},{"issue":"2","key":"604_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/s0301-472x(99)00140-x","volume":"28","author":"A Amiel","year":"2000","unstructured":"Amiel A, Kitay-Cohen Y, Fejgin MD et al (2000) Replication status as a marker for predisposition for lymphoma in patients with chronic hepatitis C with and without cryoglobulinemia. Exp Hematol 28(2):156\u2013160. https:\/\/doi.org\/10.1016\/s0301-472x(99)00140-x","journal-title":"Exp Hematol"},{"issue":"3","key":"604_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/hep.22703","volume":"49","author":"Y Arase","year":"2009","unstructured":"Arase Y, Suzuki F, Suzuki Y et al (2009) Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49(3):739\u2013744. https:\/\/doi.org\/10.1002\/hep.22703","journal-title":"Hepatology"},{"issue":"10","key":"604_CR14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/j.1872-034X.2011.00845.x","volume":"41","author":"Y Arase","year":"2011","unstructured":"Arase Y, Suzuki F, Kawamura Y et al (2011) Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res 41(10):946\u2013954. https:\/\/doi.org\/10.1111\/j.1872-034X.2011.00845.x","journal-title":"Hepatol Res"},{"issue":"21","key":"604_CR15","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","volume":"128","author":"L Arcaini","year":"2016","unstructured":"Arcaini L, Besson C, Frigeni M et al (2016) Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood 128(21):2527\u20132532. https:\/\/doi.org\/10.1182\/blood-2016-05-714667","journal-title":"Blood"},{"issue":"8","key":"604_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/jclinpath-2014-202352","volume":"67","author":"C Augello","year":"2014","unstructured":"Augello C, Gianelli U, Savi F et al (2014) MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma. J Clin Pathol 67(8):697\u2013701. https:\/\/doi.org\/10.1136\/jclinpath-2014-202352","journal-title":"J Clin Pathol"},{"issue":"2","key":"604_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1385\/MO:20:2:165","volume":"20","author":"A Avil\u00e9s","year":"2003","unstructured":"Avil\u00e9s A, Valdez L, Halabe J et al (2003) No association between lymphoma and hepatitis C virus. Med Oncol 20(2):165\u2013168. https:\/\/doi.org\/10.1385\/MO:20:2:165","journal-title":"Med Oncol"},{"key":"604_CR18","doi-asserted-by":"publisher","unstructured":"Bagaglio S, Uberti-Foppa C, Sagnelli C et al (2020) HIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy. https:\/\/doi.org\/10.1007\/s15010-020-01434-3","DOI":"10.1007\/s15010-020-01434-3"},{"issue":"2","key":"604_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000268853","volume":"123","author":"DJ Becker","year":"2010","unstructured":"Becker DJ, Sevilla DW, O\u2019Connor O (2010) Concurrent and apposed hepatocellular carcinoma and small lymphocytic lymphoma\/chronic lymphocytic leukemia in a patient with hepatitis C virus. Acta Haematol 123(2):77\u201380. https:\/\/doi.org\/10.1159\/000268853","journal-title":"Acta Haematol"},{"issue":"6","key":"604_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11904-016-0333-9","volume":"13","author":"R Bedimo","year":"2016","unstructured":"Bedimo R, Abodunde O (2016) Metabolic and cardiovascular complications in HIV\/HCV-co-infected patients. Curr HIV\/AIDS Rep 13(6):328\u2013339. https:\/\/doi.org\/10.1007\/s11904-016-0333-9","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"8","key":"604_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/lt.25060","volume":"24","author":"J Beig","year":"2018","unstructured":"Beig J, Orr D, Harrison B, Gane E (2018) Hepatitis C virus eradication with new interferon-free treatment improves metabolic profile in hepatitis C virus-related liver transplant recipients. Liver Transpl 24(8):1031\u20131039. https:\/\/doi.org\/10.1002\/lt.25060","journal-title":"Liver Transpl"},{"issue":"4","key":"604_CR01","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cgh.2016.09.158","volume":"15","author":"M Bonacci","year":"2017","unstructured":"Bonacci M, Lens S, Londo\u00f1o MC et al (2017) Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated Cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol 15(4):575\u2013583.e1. https:\/\/doi.org\/10.1016\/j.cgh.2016.09.158","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"604_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4239\/wjd.v5.i1.52","volume":"5","author":"SK Bose","year":"2014","unstructured":"Bose SK, Ray R (2014) Hepatitis C virus infection and insulin resistance. World J Diabetes 5(1):52\u201358. https:\/\/doi.org\/10.4239\/wjd.v5.i1.52","journal-title":"World J Diabetes"},{"issue":"1\u20132","key":"604_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3109\/10428199609067589","volume":"21","author":"AM Brind","year":"1996","unstructured":"Brind AM, Watson JP, Burt A et al (1996) Non-Hodgkin\u2019s lymphoma and hepatitis C virus infection. Leuk Lymphoma 21(1\u20132):127\u2013130. https:\/\/doi.org\/10.3109\/10428199609067589","journal-title":"Leuk Lymphoma"},{"issue":"47","key":"604_CR24","first-page":"2991","volume":"12","author":"JC Brouet","year":"1983","unstructured":"Brouet JC (1983) Les cryoglobulin\u00e9mies [Cryoglobulinemias]. Presse Med 12(47):2991\u20132996. French","journal-title":"Presse Med"},{"issue":"4","key":"604_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/cid\/cix359","volume":"65","author":"AA Butt","year":"2017","unstructured":"Butt AA, Yan P, Chew KW et al (2017) Risk of acute myocardial infarction among hepatitis C virus (HCV)-positive and HCV-negative men at various lipid levels: results from ERCHIVES. Clin Infect Dis 65(4):557\u2013565. https:\/\/doi.org\/10.1093\/cid\/cix359","journal-title":"Clin Infect Dis"},{"issue":"1","key":"604_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/apt.14799","volume":"48","author":"AA Butt","year":"2018","unstructured":"Butt AA, Ren Y, Puenpatom A et al (2018) Effectiveness, treatment completion and safety of sofosbuvir\/ledipasvir and paritaprevir\/ritonavir\/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Aliment Pharmacol Ther 48(1):35\u201343. https:\/\/doi.org\/10.1111\/apt.14799","journal-title":"Aliment Pharmacol Ther"},{"key":"604_CR27","doi-asserted-by":"publisher","unstructured":"Butt AA, Yan P, Aslam S et al (2019) Hepatitis C virus treatment with directly acting agents reduces the risk of incident diabetes -results from ERCHIVES. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciz304","DOI":"10.1093\/cid\/ciz304"},{"issue":"3","key":"604_CR28","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/art.20958","volume":"52","author":"P Cacoub","year":"2005","unstructured":"Cacoub P, Saadoun D, Limal N et al (2005) Pegylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 52(3):911\u2013915. https:\/\/doi.org\/10.1002\/art.20958","journal-title":"Arthritis Rheum"},{"issue":"Suppl 5","key":"604_CR29","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1016\/j.dld.2014.10.005","volume":"46","author":"P Cacoub","year":"2014","unstructured":"Cacoub P, Gragnani L, Comarmond C et al (2014) Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver dis 46(Suppl 5):S165\u2013S173. https:\/\/doi.org\/10.1016\/j.dld.2014.10.005","journal-title":"Dig Liver dis"},{"issue":"11","key":"604_CR30","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1136\/gutjnl-2018-316234","volume":"67","author":"P Cacoub","year":"2018","unstructured":"Cacoub P, Desbois AC, Comarmond C et al (2018a) Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut 67(11):2025\u20132034. https:\/\/doi.org\/10.1136\/gutjnl-2018-316234","journal-title":"Gut"},{"key":"604_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ahj.2017.10.024","volume":"198","author":"P Cacoub","year":"2018","unstructured":"Cacoub P, Nahon P, Layese R et al (2018b) Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. Am Heart J 198:4\u201317. https:\/\/doi.org\/10.1016\/j.ahj.2017.10.024","journal-title":"Am Heart J"},{"issue":"6","key":"604_CR32","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","volume":"66","author":"JL Calleja","year":"2017","unstructured":"Calleja JL, Crespo J, Rinc\u00f3n D et al (2017) Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort. J Hepatol 66(6):1138\u20131148. https:\/\/doi.org\/10.1016\/j.jhep.2017.01.028","journal-title":"J Hepatol"},{"key":"604_CR33","doi-asserted-by":"publisher","unstructured":"Calogero A, Sagnelli E, Creta M et al (2019) Eradication of HCV infection with the direct-acting antiviral therapy in renal allograft recipients. BioMed Res Int 4674560, 8 p. https:\/\/doi.org\/10.1155\/2019\/4674560. Erratum to Eradication of HCV infection with the direct-acting antiviral therapy in renal allograft recipients. BioMed Res Int 2019: 8797329, 1 p, 2019. https:\/\/doi.org\/10.1155\/2019\/8797329","DOI":"10.1155\/2019\/4674560 10.1155\/2019\/8797329"},{"issue":"7","key":"604_CR34","doi-asserted-by":"publisher","first-page":"e0219396","DOI":"10.1371\/journal.pone.0219396","volume":"14","author":"S Cammarota","year":"2019","unstructured":"Cammarota S, Citarella A, Guida A et al (2019) The inpatient hospital burden of comorbidities in HCV-infected patients: a population-based study in two Italian regions with high HCV endemicity (the BaCH study). PLoS One 14(7):e0219396. https:\/\/doi.org\/10.1371\/journal.pone.0219396","journal-title":"PLoS One"},{"issue":"10","key":"604_CR35","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.4049\/jimmunol.174.10.6532","volume":"174","author":"M Carbonari","year":"2005","unstructured":"Carbonari M, Caprini E, Tedesco T et al (2005) Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol 174(10):6532\u20136539. https:\/\/doi.org\/10.4049\/jimmunol.174.10.6532","journal-title":"J Immunol"},{"issue":"10","key":"604_CR36","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1111\/liv.12897","volume":"35","author":"P Carrier","year":"2015","unstructured":"Carrier P, Jaccard A, Jacques J et al (2015) HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int 35(10):2222\u20132227. https:\/\/doi.org\/10.1111\/liv.12897","journal-title":"Liver Int"},{"issue":"7","key":"604_CR37","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/00365521.2018.1473486","volume":"53","author":"JR Carvalho","year":"2018","unstructured":"Carvalho JR, Velosa J, Serejo F (2018) Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication \u2013 comparison of the new direct-acting antiviral agents with the old regimens. Scand J Gastroenterol 53(7):857\u2013863. https:\/\/doi.org\/10.1080\/00365521.2018.1473486","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"604_CR38","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1016\/j.cgh.2015.04.002","volume":"13","author":"E Chak","year":"2015","unstructured":"Chak E, Schulze C, Runyon BA (2015) Rapid resolution of hepatitis C virus-associated Cryoglobulin rash with use of direct-acting antivirals. Clin Gastroenterol Hepatol 13(11):e166\u2013e167. https:\/\/doi.org\/10.1016\/j.cgh.2015.04.002","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"604_CR39","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1182\/blood-2007-07-101717","volume":"111","author":"ED Charles","year":"2008","unstructured":"Charles ED, Green RM, Marukian S et al (2008) Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 111(3):1344\u20131356. https:\/\/doi.org\/10.1182\/blood-2007-07-101717","journal-title":"Blood"},{"issue":"1","key":"604_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/infdis\/jix517","volume":"217","author":"CS Chaudhury","year":"2017","unstructured":"Chaudhury CS, Sheehan J, Chairez C et al (2017) No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV. J Infect Dis 217(1):47\u201350. https:\/\/doi.org\/10.1093\/infdis\/jix517","journal-title":"J Infect Dis"},{"issue":"2","key":"604_CR41","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/jmv.24954","volume":"90","author":"A Ciancio","year":"2018","unstructured":"Ciancio A, Bosio R, Bo S et al (2018) Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol 90(2):320\u2013327. https:\/\/doi.org\/10.1002\/jmv.24954","journal-title":"J Med Virol"},{"issue":"4","key":"604_CR42","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/hep.510290422","volume":"29","author":"JD Collier","year":"1999","unstructured":"Collier JD, Zanke B, Moore M et al (1999) No association between hepatitis C and B-cell lymphoma. Hepatology 29(4):1259\u20131261. https:\/\/doi.org\/10.1002\/hep.510290422","journal-title":"Hepatology"},{"key":"604_CR43","doi-asserted-by":"publisher","unstructured":"Comarmond C, Garrido M, Pol S, et al (2017) Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C virus-induced Cryoglobulinemia Vasculitis. Gastroenterology 152(8):2052\u20132062. e2. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.037","DOI":"10.1053\/j.gastro.2017.02.037"},{"key":"604_CR44","doi-asserted-by":"crossref","unstructured":"Coppola N, Pisaturo M, Guastafierro S et al (2012) Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 44(1).49\u201354","DOI":"10.1016\/j.dld.2011.07.016"},{"issue":"2","key":"604_CR45","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cgh.2013.05.008","volume":"12","author":"N Coppola","year":"2014","unstructured":"Coppola N, Zampino R, Bellini G et al (2014) Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 12(2):334\u2013340. https:\/\/doi.org\/10.1016\/j.cgh.2013.05.008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"604_CR46","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1111\/liv.12781","volume":"35","author":"N Coppola","year":"2015","unstructured":"Coppola N, Rosa Z, Cirillo G et al (2015) TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. Liver Int 35(8):1959\u20131963. https:\/\/doi.org\/10.1111\/liv.12781","journal-title":"Liver Int"},{"issue":"5","key":"604_CR47","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s40620-019-00608-z","volume":"32","author":"N Coppola","year":"2019","unstructured":"Coppola N, Portunato F, Buonomo AR et al (2019) Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. J Nephrol 32(5):763\u2013773. https:\/\/doi.org\/10.1007\/s40620-019-00608-z","journal-title":"J Nephrol"},{"issue":"10","key":"604_CR48","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.cgh.2006.06.026","volume":"4","author":"KE Corey","year":"2006","unstructured":"Corey KE, Ross AS, Wurcel et al (2006) Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol 4(10):1278\u20131282. https:\/\/doi.org\/10.1016\/j.cgh.2006.06.026","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"604_CR49","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/00325481.2015.1021660","volume":"127","author":"SL Cornella","year":"2015","unstructured":"Cornella SL, Stine JG, Kelly V et al (2015) Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series. Postgrad Med 127(4):413\u2013417. https:\/\/doi.org\/10.1080\/00325481.2015.1021660","journal-title":"Postgrad Med"},{"issue":"2","key":"604_CR50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.dld.2019.11.006","volume":"52","author":"R D\u2019Ambrosio","year":"2020","unstructured":"D\u2019Ambrosio R, Pasulo L, Giorgini A et al (2020) Renal safety in 3264 HCV patients treated with DAA-based regimens: results from a large Italian real-life study. Dig Liver Dis 52(2):190\u2013198. https:\/\/doi.org\/10.1016\/j.dld.2019.11.006","journal-title":"Dig Liver Dis"},{"issue":"1","key":"604_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhep.2008.03.016","volume":"49","author":"CY Dai","year":"2008","unstructured":"Dai CY, Chuang WL, Ho CK et al (2008) Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 49(1):9\u201316. https:\/\/doi.org\/10.1016\/j.jhep.2008.03.016","journal-title":"J Hepatol"},{"issue":"23","key":"604_CR52","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1038\/onc.2015.364","volume":"35","author":"B Dai","year":"2016","unstructured":"Dai B, Chen AY, Corkum CP et al (2016) Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders. Oncogene 35(23):2979\u20132990. https:\/\/doi.org\/10.1038\/onc.2015.364","journal-title":"Oncogene"},{"issue":"11","key":"604_CR02","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","volume":"15","author":"L Dal Maso","year":"2006","unstructured":"Dal Maso L, Franceschi S (2006) Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomark Prev 15(11):2078\u20132085. https:\/\/doi.org\/10.1158\/1055-9965.EPI-06-0308","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"11","key":"604_CR53","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1056\/NEJMra1208642","volume":"369","author":"F Dammacco","year":"2013","unstructured":"Dammacco F, Sansonno D (2013) Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 369(11):1035\u20131045. https:\/\/doi.org\/10.1056\/NEJMra1208642","journal-title":"N Engl J Med"},{"issue":"3","key":"604_CR54","first-page":"1","volume":"58","author":"D Daniels","year":"2009","unstructured":"Daniels D, Grytdal S, Wasley A et al (2009) Surveillance for acute viral hepatitis \u2013 United States, 2007. MMWR Surveill Summ 58(3):1\u201327","journal-title":"MMWR Surveill Summ"},{"issue":"4","key":"604_CR55","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4093\/dmj.2017.41.4.316","volume":"41","author":"AA Dawood","year":"2017","unstructured":"Dawood AA, Nooh MZ, Elgamal AA (2017) Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4. Diabetes Metab J 41(4):316\u2013321. https:\/\/doi.org\/10.4093\/dmj.2017.41.4.316","journal-title":"Diabetes Metab J"},{"issue":"11","key":"604_CR56","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.humimm.2004.08.183","volume":"65","author":"V De Re","year":"2004","unstructured":"De Re V, Caggiari L, Talamini R et al (2004) Hepatitis C virus-related hepatocellular carcinoma and B-cell lymphoma patients show a different profile of major histocompatibility complex class II alleles. Hum Immunol 65(11):1397\u20131404. https:\/\/doi.org\/10.1016\/j.humimm.2004.08.183","journal-title":"Hum Immunol"},{"issue":"2","key":"604_CR57","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1399-0039.2009.01414.x","volume":"75","author":"V De Re","year":"2009","unstructured":"De Re V, Caggiari L, Monti G et al (2009) HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia. Tissue Antigens 75(2):127\u2013135. https:\/\/doi.org\/10.1111\/j.1399-0039.2009.01414.x","journal-title":"Tissue Antigens"},{"key":"604_CR58","doi-asserted-by":"publisher","first-page":"623465","DOI":"10.1155\/2012\/623465","volume":"2012","author":"V De Re","year":"2012","unstructured":"De Re V, Caggiari L, Garziera M et al (2012) Molecular signature in HCV-positive lymphomas. Clin Dev Immunol 2012:623465. https:\/\/doi.org\/10.1155\/2012\/623465","journal-title":"Clin Dev Immunol"},{"issue":"4","key":"604_CR59","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cgh.2008.02.011","volume":"6","author":"S de Sanjose","year":"2008","unstructured":"de Sanjose S, Benavente Y, Vajdic CM et al (2008) Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol 6(4):451\u2013458. https:\/\/doi.org\/10.1016\/j.cgh.2008.02.011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"604_CR60","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1182\/blood.V90.2.776.776_776_782","volume":"90","author":"S De Vita","year":"1997","unstructured":"De Vita S, Sacco C, Sansonno D et al (1997) Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 90(2):776\u2013782","journal-title":"Blood"},{"issue":"3","key":"604_CR61","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10238-020-00615-6","volume":"20","author":"I Defrancesco","year":"2020","unstructured":"Defrancesco I, Zerbi C, Rattotti S et al (2020) HCV infection and non-Hodgkin lymphomas: an evolving story. Clin Exp Med 20(3):321\u2013328. https:\/\/doi.org\/10.1007\/s10238-020-00615-6","journal-title":"Clin Exp Med"},{"issue":"9","key":"604_CR62","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3748\/wjg.v23.i9.1697","volume":"23","author":"AC Desbois","year":"2017","unstructured":"Desbois AC, Cacoub P (2017) Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review. World J Gastroenterol 23(9):1697\u20131711. https:\/\/doi.org\/10.3748\/wjg.v23.i9.1697","journal-title":"World J Gastroenterol"},{"issue":"5","key":"604_CR63","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/liv.13064","volume":"36","author":"F Domont","year":"2016","unstructured":"Domont F, Cacoub P (2016) Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int 36(5):621\u2013627. https:\/\/doi.org\/10.1111\/liv.13064","journal-title":"Liver Int"},{"issue":"2","key":"604_CR64","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1128\/JVI.02516-15","volume":"90","author":"F Douam","year":"2015","unstructured":"Douam F, Bobay LM, Maurin G et al (2015) Specialization of hepatitis C virus envelope glycoproteins for B lymphocytes in chronically infected patients. J Virol 90(2):992\u20131008. https:\/\/doi.org\/10.1128\/JVI.02516-15","journal-title":"J Virol"},{"key":"604_CR65","doi-asserted-by":"publisher","first-page":"6150861","DOI":"10.1155\/2018\/6150861","volume":"2018","author":"S Drazilova","year":"2018","unstructured":"Drazilova S, Gazda J, Janicko M et al (2018) Chronic hepatitis C association with diabetes mellitus and cardiovascular risk in the era of DAA therapy. Can J Gastroenterol Hepatol 2018:6150861. https:\/\/doi.org\/10.1155\/2018\/6150861","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"1","key":"604_CR66","doi-asserted-by":"publisher","first-page":"1435124","DOI":"10.1080\/19932820.2018.1435124","volume":"13","author":"G El Sagheer","year":"2018","unstructured":"El Sagheer G, Soliman E, Ahmad A et al (2018) Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs. Libyan J Med 13(1):1435124. https:\/\/doi.org\/10.1080\/19932820.2018.1435124","journal-title":"Libyan J Med"},{"key":"604_CR67","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/apt.15240","volume":"49","author":"HB El-Serag","year":"2019","unstructured":"El-Serag HB, Christie IC, Puenpatom A (2019) The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther 49:1442\u20131447","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"604_CR68","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/ajg.2017.49","volume":"112","author":"JS Emery","year":"2017","unstructured":"Emery JS, Kuczynski M, La D et al (2017) Efficacy and safety of direct acting antivirals for the treatment of mixed Cryoglobulinemia. Am J Gastroenterol 112(8):1298\u20131308. https:\/\/doi.org\/10.1038\/ajg.2017.49","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"604_CR69","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jhep.2007.07.033","volume":"48","author":"JI Esteban","year":"2008","unstructured":"Esteban JI, Sauleda S, Quer J (2008) The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48(1):148\u2013162. https:\/\/doi.org\/10.1016\/j.jhep.2007.07.033","journal-title":"J Hepatol"},{"issue":"2","key":"604_CR70","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, & European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, & European Association for the Study of the Liver (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69(2):461\u2013511. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.026","journal-title":"J Hepatol"},{"issue":"1","key":"604_CR71","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/ard.2006.067637","volume":"67","author":"M Fabris","year":"2008","unstructured":"Fabris M, Quartuccio L, Salvin S et al (2008) Fibronectin gene polymorphisms are associated with the development of B-cell lymphoma in type II mixed cryoglobulinemia. Ann Rheum Dis 67(1):80\u201383. https:\/\/doi.org\/10.1136\/ard.2006.067637","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"604_CR72","doi-asserted-by":"publisher","first-page":"851","DOI":"10.5604\/01.3001.0010.5275","volume":"16","author":"F Fabrizi","year":"2017","unstructured":"Fabrizi F, Donato FM, Messa P (2017) Hepatitis C and its metabolic complications in kidney disease. Ann Hepatol 16(6):851\u2013861. https:\/\/doi.org\/10.5604\/01.3001.0010.5275","journal-title":"Ann Hepatol"},{"issue":"3","key":"604_CR73","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.nefro.2019.07.007","volume":"40","author":"F Fabrizi","year":"2020","unstructured":"Fabrizi F, Cerutti R, Dixit V et al (2020) The impact of antiviral therapy for HCV on kidney disease: a systematic review and meta-analysis. Nefrologia 40(3):299\u2013310. https:\/\/doi.org\/10.1016\/j.nefro.2019.07.007","journal-title":"Nefrologia"},{"issue":"5","key":"604_CR74","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.cmi.2016.09.021","volume":"23","author":"C Fabrizio","year":"2017","unstructured":"Fabrizio C, Procopio A, Scudeller L et al (2017) HCV and diabetes: towards a \u2018sustained\u2019 glycaemic improvement after treatment with DAAs? Clin Microbiol Infect 23(5):342\u2013343. https:\/\/doi.org\/10.1016\/j.cmi.2016.09.021","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"604_CR75","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000493807","volume":"140","author":"A Fayed","year":"2018","unstructured":"Fayed A, El Nokeety MM, Samy Abdelaziz T et al (2018) Incidence and characteristics of de novo renal Cryoglobulinemia after direct-acting antivirals treatment in an Egyptian hepatitis C cohort. Nephron 140(4):275\u2013281. https:\/\/doi.org\/10.1159\/000493807","journal-title":"Nephron"},{"issue":"15","key":"604_CR76","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-06-0154","volume":"12","author":"G Feldmann","year":"2006","unstructured":"Feldmann G, Nischalke HD, Nattermann J et al (2006) Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. Clin Cancer Res 12(15):4491\u20134498. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0154","journal-title":"Clin Cancer Res"},{"issue":"5","key":"604_CR77","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/v5051292","volume":"5","author":"DJ Felmlee","year":"2013","unstructured":"Felmlee DJ, Hafirassou ML, Lefevre M et al (2013) Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses 5(5):1292\u20131324. https:\/\/doi.org\/10.3390\/v5051292","journal-title":"Viruses"},{"issue":"2","key":"604_CR78","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/ndt\/gfr236","volume":"27","author":"B Feng","year":"2012","unstructured":"Feng B, Eknoyan G, Guo ZS et al (2012) Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Nephrol Dial Transplant 27(2):640\u2013646. https:\/\/doi.org\/10.1093\/ndt\/gfr236","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"604_CR79","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1365-2141.1994.tb05036.x","volume":"88","author":"C Ferri","year":"1994","unstructured":"Ferri C, Caracciolo F, Zignego AL et al (1994) Hepatitis C virus infection in patients with non-Hodgkin\u2019s lymphoma. Br J Haematol 88(2):392\u2013394. https:\/\/doi.org\/10.1111\/j.1365-2141.1994.tb05036.x","journal-title":"Br J Haematol"},{"issue":"5","key":"604_CR80","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2893.2012.01591.x","volume":"19","author":"NF Fletcher","year":"2012","unstructured":"Fletcher NF, McKeating JA (2012) Hepatitis C virus and the brain. J Viral Hepat 19(5):301\u2013306. https:\/\/doi.org\/10.1111\/j.1365-2893.2012.01591.x","journal-title":"J Viral Hepat"},{"issue":"11","key":"604_CR03","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/sj.bjc.6603472","volume":"95","author":"S Franceschi","year":"2006","unstructured":"Franceschi S, Polesel J, Rickenbach M et al (2006) Hepatitis C virus and non-Hodgkin\u2019s lymphoma: findings from the Swiss HIV Cohort Study. Br J Cancer 95(11):1598\u20131602. https:\/\/doi.org\/10.1038\/sj.bjc.6603472","journal-title":"Br J Cancer"},{"issue":"5","key":"604_CR81","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/s41375-019-0687-2","volume":"34","author":"M Frigeni","year":"2020","unstructured":"Frigeni M, Besson C, Visco C et al (2020) Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia 34(5):1462\u20131466. https:\/\/doi.org\/10.1038\/s41375-019-0687-2","journal-title":"Leukemia"},{"issue":"4","key":"604_CR82","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1378\/chest.122.4.1348","volume":"122","author":"A Frustaci","year":"2002","unstructured":"Frustaci A, Calabrese F, Chimenti C et al (2002) Lone hepatitis C virus myocarditis responsive to immunosuppressive therapy. Chest 122(4):1348\u20131356. https:\/\/doi.org\/10.1378\/chest.122.4.1348","journal-title":"Chest"},{"issue":"29","key":"604_CR83","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.4254\/wjh.v8.i29.1244","volume":"8","author":"G Galati","year":"2016","unstructured":"Galati G, Rampa L, Vespasiani-Gentilucci U et al (2016) Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy. World J Hepatol 8(29):1244\u20131250. https:\/\/doi.org\/10.4254\/wjh.v8.i29.1244","journal-title":"World J Hepatol"},{"issue":"9022","key":"604_CR84","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/s0140-6736(05)65593-6","volume":"348","author":"M Galli","year":"1996","unstructured":"Galli M, Pioltelli P, Zehender G et al (1996) HCV and lymphomagenesis. Lancet 348(9022):275. https:\/\/doi.org\/10.1016\/s0140-6736(05)65593-6","journal-title":"Lancet"},{"issue":"8","key":"604_CR85","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/MCG.0000000000001168","volume":"53","author":"A Gilad","year":"2019","unstructured":"Gilad A, Fricker ZP, Hsieh A et al (2019) Sustained improvement in type 2 diabetes mellitus is common after treatment of hepatitis C virus with direct-acting antiviral therapy. J Clin Gastroenterol 53(8):616\u2013620. https:\/\/doi.org\/10.1097\/MCG.0000000000001168","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"604_CR86","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1111\/j.1572-0241.2008.02002.x","volume":"103","author":"C Giordanino","year":"2008","unstructured":"Giordanino C, Bugianesi E, Smedile A et al (2008) Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol 103(10):2481\u20132487. https:\/\/doi.org\/10.1111\/j.1572-0241.2008.02002.x","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"604_CR87","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","volume":"17","author":"S Gitto","year":"2018","unstructured":"Gitto S, Cicero A, Loggi E et al (2018) Worsening of serum lipid profile after direct acting antiviral treatment. Ann Hepatol 17(1):64\u201375. https:\/\/doi.org\/10.5604\/01.3001.0010.7536","journal-title":"Ann Hepatol"},{"key":"604_CR88","unstructured":"Global Hepatitis Report (2017) WHO The Polaris Observatory HCV Collaborators Lancet. Gastroenterol Hepatol 2: 161\u2013176"},{"issue":"22(18)","key":"604_CR04","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.3748\/wjg.v22.i18.4427","volume":"14","author":"E Gonz\u00e1lez-Reimers","year":"2016","unstructured":"Gonz\u00e1lez-Reimers E, Quintero-Platt G, Mart\u00edn-Gonz\u00e1lez C et al (2016) Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol 14(22(18)):4427\u20134437. https:\/\/doi.org\/10.3748\/wjg.v22.i18.4427","journal-title":"World J Gastroenterol"},{"issue":"3","key":"604_CR89","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cld.2017.03.003","volume":"21","author":"N Goossens","year":"2017","unstructured":"Goossens N, Negro F (2017) Cardiovascular manifestations of hepatitis C virus. Clin Liver Dis 21(3):465\u2013473. https:\/\/doi.org\/10.1016\/j.cld.2017.03.003","journal-title":"Clin Liver Dis"},{"issue":"9","key":"604_CR90","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.dld.2014.05.017","volume":"46","author":"L Gragnani","year":"2014","unstructured":"Gragnani L, Fabbrizzi A, Triboli E et al (2014) Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Dig Liver Dis 46(9):833\u2013837. https:\/\/doi.org\/10.1016\/j.dld.2014.05.017","journal-title":"Dig Liver Dis"},{"issue":"4","key":"604_CR91","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/hep.27623","volume":"61","author":"L Gragnani","year":"2015","unstructured":"Gragnani L, Fognani E, Piluso A et al (2015) Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology 61(4):1145\u20131153. https:\/\/doi.org\/10.1002\/hep.27623","journal-title":"Hepatology"},{"issue":"4","key":"604_CR92","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/apt.14845","volume":"48","author":"L Gragnani","year":"2018","unstructured":"Gragnani L, Cerretelli G, Lorini S et al (2018) Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis. Aliment Pharmacol Ther 48(4):440\u2013450","journal-title":"Aliment Pharmacol Ther"},{"issue":"9011","key":"604_CR93","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/s0140-6736(96)90991-5","volume":"347","author":"J Hanley","year":"1996","unstructured":"Hanley J, Jarvis L, Simmonds P et al (1996) HCV and non-Hodgkin lymphoma. Lancet 347(9011):1339. https:\/\/doi.org\/10.1016\/s0140-6736(96)90991-5","journal-title":"Lancet"},{"issue":"9","key":"604_CR94","doi-asserted-by":"publisher","first-page":"e0163644","DOI":"10.1371\/journal.pone.0163644","volume":"11","author":"S Hashimoto","year":"2016","unstructured":"Hashimoto S, Yatsuhashi H, Abiru et al (2016) Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment. PLoS One 11(9):e0163644. https:\/\/doi.org\/10.1371\/journal.pone.0163644","journal-title":"PLoS One"},{"key":"604_CR05","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2147\/IDR.S167093","volume":"11","author":"AM Hassan","year":"2018","unstructured":"Hassan AM, Osman HA, Mahmoud HS et al (2018) Sofosbuvir-daclatasvir improves hepatitis C virus-induced mixed cryoglobulinemia: Upper Egypt experience. Infect Drug Resist 11:895\u2013901. https:\/\/doi.org\/10.2147\/IDR.S167093. Erratum in: Infect Drug Resist. 2019 May 29;12:1469","journal-title":"Infect Drug Resist"},{"issue":"3","key":"604_CR95","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ajh.1101","volume":"67","author":"P Hausfater","year":"2001","unstructured":"Hausfater P, Cacoub P, Sterkers Y et al (2001) Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France. Am J Hematol 67(3):168\u2013171. https:\/\/doi.org\/10.1002\/ajh.1101","journal-title":"Am J Hematol"},{"issue":"2","key":"604_CR96","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/sdi.12759","volume":"32","author":"JB Henson","year":"2019","unstructured":"Henson JB, Sise ME (2019) The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial 32(2):108\u2013118. https:\/\/doi.org\/10.1111\/sdi.12759","journal-title":"Semin Dial"},{"issue":"11","key":"604_CR97","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/ijc.30372","volume":"139","author":"J Hosry","year":"2016","unstructured":"Hosry J, Mahale P, Turturro F et al (2016) Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. Int J Cancer 139(11):2519\u20132528. https:\/\/doi.org\/10.1002\/ijc.30372","journal-title":"Int J Cancer"},{"issue":"3","key":"604_CR98","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jhep.2014.09.022","volume":"62","author":"YH Hsu","year":"2015","unstructured":"Hsu YH, Muo CH, Liu CY et al (2015a) Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study. J Hepatol 62(3):519\u2013525. https:\/\/doi.org\/10.1016\/j.jhep.2014.09.022","journal-title":"J Hepatol"},{"issue":"3","key":"604_CR99","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","volume":"64","author":"YC Hsu","year":"2015","unstructured":"Hsu YC, Ho HJ, Huang YT et al (2015b) Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 64(3):495\u2013503. https:\/\/doi.org\/10.1136\/gutjnl-2014-308163","journal-title":"Gut"},{"key":"604_CR100","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.kjms.2017.07.003","volume":"33","author":"JF Huang","year":"2017","unstructured":"Huang JF, Huang CF, Yeh ML et al (2017) The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. Kaohsiung J Med Sci 33:567\u2013571","journal-title":"Kaohsiung J Med Sci"},{"issue":"6","key":"604_CR101","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","volume":"125","author":"JM Hui","year":"2003","unstructured":"Hui JM, Sud A, Farrell et al (2003) Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 125(6):1695\u20131704. https:\/\/doi.org\/10.1053\/j.gastro.2003.08.032","journal-title":"Gastroenterology"},{"issue":"9","key":"604_CR102","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2337\/dc17-0485","volume":"40","author":"J Hum","year":"2017","unstructured":"Hum J, Jou JH, Green et al (2017) Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus. Diabetes Care 40(9):1173\u20131180. https:\/\/doi.org\/10.2337\/dc17-0485","journal-title":"Diabetes Care"},{"issue":"8","key":"604_CR103","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1007\/s10620-014-3085-7","volume":"59","author":"K Humphries","year":"2014","unstructured":"Humphries K, Darling JM, Barritt AS 4th (2014) Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature. Dig Dis Sci 59(8):2007\u20132012. https:\/\/doi.org\/10.1007\/s10620-014-3085-7","journal-title":"Dig Dis Sci"},{"issue":"9","key":"604_CR104","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2169\/internalmedicine.1514-18","volume":"58","author":"T Ichikawa","year":"2019","unstructured":"Ichikawa T, Miyaaki H, Miuma S et al (2019) Carotid intima-media thickness and small dense low-density lipoprotein cholesterol increase after one year of treatment with direct-acting antivirals in patients with hepatitis C virus infection. Intern Med 58(9):1209\u20131215. https:\/\/doi.org\/10.2169\/internalmedicine.1514-18","journal-title":"Intern Med"},{"issue":"4","key":"604_CR105","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000484237","volume":"96","author":"A Ikeda","year":"2017","unstructured":"Ikeda A, Ikeda K, Takai et al (2017) Hepatitis C treatment with Sofosbuvir and Ledipasvir accompanied by immediate improvement in hemoglobin A1c. Digestion 96(4):228\u2013230. https:\/\/doi.org\/10.1159\/000484237","journal-title":"Digestion"},{"issue":"1","key":"604_CR106","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1253\/circj.67.26","volume":"67","author":"Y Ishizaka","year":"2003","unstructured":"Ishizaka Y, Ishizaka N, Takahashi E et al (2003) Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 67(1):26\u201330. https:\/\/doi.org\/10.1253\/circj.67.26","journal-title":"Circ J"},{"key":"604_CR107","doi-asserted-by":"publisher","unstructured":"Iwane K, Kayahara T, Takabatake H et al (2019) Recurrence of malignant lymphoma immediately after treatment for hepatitis C virus using direct-acting antivirals. Nihon Shokakibyo Gakkai Zasshi 116(2):177\u2013183. Japanese. https:\/\/doi.org\/10.11405\/nisshoshi.116.177","DOI":"10.11405\/nisshoshi.116.177"},{"key":"604_CR108","doi-asserted-by":"publisher","unstructured":"Kanwal F, White DL, Tavakoli-Tabasi S et al (2014) Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Clin Gastroenterol Hepatol 12(2): 327\u2013333.e1. https:\/\/doi.org\/10.1016\/j.cgh.2013.08.034","DOI":"10.1016\/j.cgh.2013.08.034"},{"issue":"3","key":"604_CR109","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1309\/REV9-FDTM-5NGC-HBWY","volume":"113","author":"SJ Karavattathayyil","year":"2000","unstructured":"Karavattathayyil SJ, Kalkeri G, Liu HJ et al (2000) Detection of hepatitis C virus RNA sequences in B-cell non-Hodgkin lymphoma. Am J Clin Pathol 113(3):391\u2013398. https:\/\/doi.org\/10.1309\/REV9-FDTM-5NGC-HBWY","journal-title":"Am J Clin Pathol"},{"issue":"23","key":"604_CR110","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1182\/blood-2010-05-283358","volume":"116","author":"Y Kasama","year":"2011","unstructured":"Kasama Y, Sekiguchi S, Saito M et al (2011) Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 116(23):4926\u20134933. https:\/\/doi.org\/10.1182\/blood-2010-05-283358","journal-title":"Blood"},{"issue":"1","key":"604_CR111","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/CRD.0000000000000031","volume":"23","author":"V Katsi","year":"2015","unstructured":"Katsi V, Felekos I, Skevofilax S et al (2015) Cardiovascular disease and hepatitis C virus infection: an irrelevant statement or a hot relationship? Cardiol Rev 23(1):11\u201317. https:\/\/doi.org\/10.1097\/CRD.0000000000000031","journal-title":"Cardiol Rev"},{"issue":"12","key":"604_CR112","doi-asserted-by":"publisher","first-page":"e0209615","DOI":"10.1371\/journal.pone.0209615","volume":"13","author":"N Kawagishi","year":"2018","unstructured":"Kawagishi N, Suda G, Nakamura A et al (2018) Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS One 13(12):e0209615. https:\/\/doi.org\/10.1371\/journal.pone.0209615","journal-title":"PLoS One"},{"issue":"5","key":"604_CR113","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/14397595.2016.1253814","volume":"27","author":"T Koga","year":"2017","unstructured":"Koga T, Kawashiri SY, Nakao K et al (2017) Successful ledipasvir\u2009+\u2009sofosbuvir treatment of active synovitis in a rheumatoid arthritis patient with hepatitis C virus-related mixed cryoglobulinemia. Mod Rheumatol 27(5):917\u2013918. https:\/\/doi.org\/10.1080\/14397595.2016.1253814","journal-title":"Mod Rheumatol"},{"issue":"10","key":"604_CR114","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","volume":"5","author":"LH Kuller","year":"2008","unstructured":"Kuller LH, Tracy R, Belloso W et al (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5(10):e203. https:\/\/doi.org\/10.1371\/journal.pmed.0050203","journal-title":"PLoS Med"},{"issue":"8","key":"604_CR115","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.autrev.2007.03.010","volume":"6","author":"DA Landau","year":"2007","unstructured":"Landau DA, Saadoun D, Calabrese LH et al (2007) The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev 6(8):581\u2013587. https:\/\/doi.org\/10.1016\/j.autrev.2007.03.010","journal-title":"Autoimmun Rev"},{"issue":"3","key":"604_CR116","first-page":"139","volume":"42","author":"S Lanini","year":"2019","unstructured":"Lanini S, Bartolini B, Taibi C et al (2019) Early improvement of glycaemic control after virus clearance in patients with chronic hepatitis C and severe liver fibrosis: a cohort study. New Microbiol 42(3):139\u2013144","journal-title":"New Microbiol"},{"issue":"7","key":"604_CR117","first-page":"434","volume":"8","author":"N Latt","year":"2012","unstructured":"Latt N, Alachkar N, Gurakar A (2012) Hepatitis C virus and its renal manifestations: a review and update. Gastroenterol Hepatol 8(7):434\u2013445","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"604_CR118","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13075-017-1280-6","volume":"19","author":"G Lauletta","year":"2017","unstructured":"Lauletta G, Russi S, Pavone F et al (2017) Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience. Arthritis Res Ther 19(1):74. https:\/\/doi.org\/10.1186\/s13075-017-1280-6","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"604_CR119","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee MH, Yang HI, Lu SN et al (2012) Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 206(4):469\u2013477. https:\/\/doi.org\/10.1093\/infdis\/jis385","journal-title":"J Infect Dis"},{"issue":"7","key":"604_CR120","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/liv.13336","volume":"37","author":"T Li","year":"2017","unstructured":"Li T, Qu Y, Guo Y et al (2017) Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int 37(7):974\u2013981. https:\/\/doi.org\/10.1111\/liv.13336","journal-title":"Liver Int"},{"issue":"6","key":"604_CR121","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/liv.14031","volume":"39","author":"J Li","year":"2019","unstructured":"Li J, Gordon SC, Rupp LB et al (2019) Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C. Liver Int 39(6):1027\u20131032. https:\/\/doi.org\/10.1111\/liv.14031","journal-title":"Liver Int"},{"issue":"1","key":"604_CR122","doi-asserted-by":"publisher","first-page":"69","DOI":"10.14309\/crj.2015.104","volume":"3","author":"LY Lim","year":"2015","unstructured":"Lim LY, La D, Cserti-Gazdewich CM et al (2015) Lymphoma remission by interferon-free HCV eradication without chemotherapy. ACG Case Rep J 3(1):69\u201370. https:\/\/doi.org\/10.14309\/crj.2015.104","journal-title":"ACG Case Rep J"},{"issue":"44","key":"604_CR123","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3748\/wjg.v22.i44.9674","volume":"22","author":"A Lonardo","year":"2016","unstructured":"Lonardo A, Ballestri S, Guaraldi G et al (2016) Fatty liver is associated with an increased risk of diabetes and cardiovascular disease \u2013 evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 22(44):9674\u20139693. https:\/\/doi.org\/10.3748\/wjg.v22.i44.9674","journal-title":"World J Gastroenterol"},{"issue":"1","key":"604_CR124","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2013.10.030","volume":"232","author":"P Loria","year":"2014","unstructured":"Loria P, Marchesini G, Nascimbeni F et al (2014) Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 232(1):99\u2013109. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.10.030","journal-title":"Atherosclerosis"},{"issue":"2","key":"604_CR125","first-page":"351","volume":"10","author":"M Luppi","year":"1996","unstructured":"Luppi M, Grazia Ferrari M, Bonaccorsi G et al (1996) Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia 10(2):351\u2013355","journal-title":"Leukemia"},{"issue":"14","key":"604_CR126","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1128\/JVI.00321-06","volume":"80","author":"K Machida","year":"2006","unstructured":"Machida K, Cheng KT, Lai CK et al (2006a) Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol 80(14):7199\u20137207. https:\/\/doi.org\/10.1128\/JVI.00321-06","journal-title":"J Virol"},{"issue":"2","key":"604_CR127","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1128\/JVI.80.2.866-874.2006","volume":"80","author":"K Machida","year":"2006","unstructured":"Machida K, Cheng KT, Sung VM et al (2006b) Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 80(2):866\u2013874. https:\/\/doi.org\/10.1128\/JVI.80.2.866-874.2006","journal-title":"J Virol"},{"issue":"8","key":"604_CR128","first-page":"436","volume":"28","author":"G Maggi","year":"1996","unstructured":"Maggi G, Bottelli R, Gola D et al (1996) Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 28(8):436\u2013440","journal-title":"Ital J Gastroenterol"},{"issue":"3","key":"604_CR129","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","volume":"67","author":"P Mahale","year":"2018","unstructured":"Mahale P, Engels EA, Li R et al (2018) The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut 67(3):553\u2013561. https:\/\/doi.org\/10.1136\/gutjnl-2017-313983","journal-title":"Gut"},{"key":"604_CR130","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jcv.2015.09.003","volume":"72","author":"M Makara","year":"2015","unstructured":"Makara M, Sulyok M, Csacsovszki O et al (2015) Successful treatment of HCV-associated cryoglobulinemia with ombitasvir\/paritaprevir\/ritonavir, dasabuvir and ribavirin: a case report. J Clin Virol 72:66\u201368. https:\/\/doi.org\/10.1016\/j.jcv.2015.09.003","journal-title":"J Clin Virol"},{"issue":"1","key":"604_CR131","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jhep.2012.07.045","volume":"58","author":"S Maruyama","year":"2013","unstructured":"Maruyama S, Koda M, Oyake N et al (2013) Myocardial injury in patients with chronic hepatitis C infection. J Hepatol 58(1):11\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2012.07.045","journal-title":"J Hepatol"},{"issue":"8","key":"604_CR132","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/gut.2006.091983","volume":"56","author":"D Marzouk","year":"2007","unstructured":"Marzouk D, Sass J, Bakr I et al (2007) Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 56(8):1105\u20131110. https:\/\/doi.org\/10.1136\/gut.2006.091983","journal-title":"Gut"},{"issue":"7","key":"604_CR133","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/liv.14119","volume":"39","author":"M Masarone","year":"2019","unstructured":"Masarone M, Persico M (2019) Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: a systematic review and meta-analysis. Liver Int 39(7):1292\u20131306. https:\/\/doi.org\/10.1111\/liv.14119","journal-title":"Liver Int"},{"key":"604_CR134","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/3-540-30822-9_7","volume":"55","author":"A Matsumori","year":"2006","unstructured":"Matsumori A (2006) Role of hepatitis C virus in cardiomyopathies. Ernst Schering Res Found Workshop 55:99\u2013120. https:\/\/doi.org\/10.1007\/3-540-30822-9_7","journal-title":"Ernst Schering Res Found Workshop"},{"issue":"3","key":"604_CR135","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1006\/bbrc.1996.0803","volume":"222","author":"A Matsumori","year":"1996","unstructured":"Matsumori A, Matoba Y, Nishio R et al (1996) Detection of hepatitis C virus RNA from the heart of patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun 222(3):678\u2013682. https:\/\/doi.org\/10.1006\/bbrc.1996.0803","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"604_CR136","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1253\/jcj.62.389","volume":"62","author":"A Matsumori","year":"1998","unstructured":"Matsumori A, Ohashi N, Hasegawa K et al (1998) Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jpn Circ J 62(5):389\u2013391. https:\/\/doi.org\/10.1253\/jcj.62.389","journal-title":"Jpn Circ J"},{"issue":"9","key":"604_CR137","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1349-7006.2004.tb03256.x","volume":"95","author":"K Matsuo","year":"2004","unstructured":"Matsuo K, Kusano A, Sugumar A et al (2004) Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 95(9):745\u2013752. https:\/\/doi.org\/10.1111\/j.1349-7006.2004.tb03256.x","journal-title":"Cancer Sci"},{"issue":"1","key":"604_CR138","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3851\/IMP3094","volume":"21","author":"S Mauss","year":"2017","unstructured":"Mauss S, Berger F, Wehmeyer MH et al (2017) Effect of antiviral therapy for HCV on lipid levels. Antivir Ther 21(1):81\u201388. https:\/\/doi.org\/10.3851\/IMP3094","journal-title":"Antivir Ther"},{"issue":"12","key":"604_CR139","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2604::AID-CNCR26>3.0.CO;2-V","volume":"77","author":"C Mazzaro","year":"1996","unstructured":"Mazzaro C, Franzin F, Tulissi P et al (1996) Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 77(12):2604\u20132613","journal-title":"Cancer"},{"issue":"8","key":"604_CR140","doi-asserted-by":"publisher","first-page":"592","DOI":"10.7326\/0003-4819-133-8-200010170-00009","volume":"133","author":"SH Mehta","year":"2000","unstructured":"Mehta SH, Brancati FL, Sulkowski MS et al (2000) Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133(8):592\u2013599. https:\/\/doi.org\/10.7326\/0003-4819-133-8-200010170-00009","journal-title":"Ann Intern Med"},{"issue":"4","key":"604_CR141","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40121-017-0171-0","volume":"6","author":"DA Mehta","year":"2017","unstructured":"Mehta DA, Cohen E, Charafeddine M et al (2017) Effect of hepatitis C treatment with Ombitasvir\/Paritaprevir\/R + Dasabuvir on renal, cardiovascular and metabolic Extrahepatic manifestations: a post-hoc analysis of phase 3 clinical trials. Infect Dis Ther 6(4):515\u2013529. https:\/\/doi.org\/10.1007\/s40121-017-0171-0","journal-title":"Infect Dis Ther"},{"issue":"3","key":"604_CR142","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/hep.27424","volume":"61","author":"EG Meissner","year":"2015","unstructured":"Meissner EG, Lee YJ, Osinusi A et al (2015) Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology 61(3):790\u2013801. https:\/\/doi.org\/10.1002\/hep.27424","journal-title":"Hepatology"},{"issue":"3","key":"604_CR143","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1182\/blood-2002-10-3230","volume":"102","author":"A Mele","year":"2003","unstructured":"Mele A, Pulsoni A, Bianco E et al (2003) Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 102(3):996\u2013999. https:\/\/doi.org\/10.1182\/blood-2002-10-3230","journal-title":"Blood"},{"issue":"8","key":"604_CR144","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1634\/theoncologist.2018-0331","volume":"24","author":"M Merli","year":"2019","unstructured":"Merli M, Frigeni M, Alric L et al (2019) Direct-acting antivirals in hepatitis C virus-associated diffuse large B-cell lymphomas. Oncologist 24(8):e720\u2013e729. https:\/\/doi.org\/10.1634\/theoncologist.2018-0331","journal-title":"Oncologist"},{"issue":"9","key":"604_CR145","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1080\/10428194.2020.1755859","volume":"61","author":"M Merli","year":"2020","unstructured":"Merli M, Defrancesco I, Visco C et al (2020) Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Leuk Lymphoma 61(9):2122\u20132128. https:\/\/doi.org\/10.1080\/10428194.2020.1755859","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"604_CR146","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1074\/jbc.M110.175018","volume":"286","author":"A Merz","year":"2011","unstructured":"Merz A, Long G, Hiet MS et al (2011) Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 286(4):3018\u20133032. https:\/\/doi.org\/10.1074\/jbc.M110.175018","journal-title":"J Biol Chem"},{"key":"604_CR147","doi-asserted-by":"publisher","unstructured":"Miailhes P, Hartig-Lavie K, Virlogeux V, et al (2018) Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia. Clin Microbiol Infect 24(11):1215.e1\u20131215.e4. https:\/\/doi.org\/10.1016\/j.cmi.2018.05.019","DOI":"10.1016\/j.cmi.2018.05.019"},{"issue":"5","key":"604_CR148","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1128\/CVI.00720-12","volume":"20","author":"M Minopetrou","year":"2013","unstructured":"Minopetrou M, Hadziyannis E, Deutsch M et al (2013) Hepatitis C virus (HCV)-related cryoglobulinemia: cryoglobulin type and anti-HCV profile. Clin Vaccine Immunol 20(5):698\u2013703. https:\/\/doi.org\/10.1128\/CVI.00720-12","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"604_CR149","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11904-019-00466-1","volume":"16","author":"A Mohanty","year":"2019","unstructured":"Mohanty A, Salameh S, Butt AA (2019) Impact of direct acting antiviral agent therapy upon Extrahepatic manifestations of hepatitis C virus infection. Curr HIV\/AIDS Rep 16(5):389\u2013394. https:\/\/doi.org\/10.1007\/s11904-019-00466-1","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"5","key":"604_CR150","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1034\/j.1600-0676.2001.210506.x","volume":"21","author":"M Montella","year":"2001","unstructured":"Montella M, Crispo A, de Bellis G et al (2001) HCV and cancer: a case-control study in a high-endemic area. Liver 21(5):335\u2013341. https:\/\/doi.org\/10.1034\/j.1600-0676.2001.210506.x","journal-title":"Liver"},{"issue":"5","key":"604_CR151","doi-asserted-by":"publisher","first-page":"CD011403","DOI":"10.1002\/14651858.CD011403.pub2","volume":"5","author":"N Montero","year":"2018","unstructured":"Montero N, Fav\u00e0 A, Rodriguez E et al (2018) Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. Cochrane Database Syst Rev 5(5):CD011403. https:\/\/doi.org\/10.1002\/14651858.CD011403.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"35","key":"604_CR152","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.4254\/wjh.v8.i35.1557","volume":"8","author":"AL Morales","year":"2016","unstructured":"Morales AL, Junga Z, Singla MB et al (2016) Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. World J Hepatol 8(35):1557\u20131563. https:\/\/doi.org\/10.4254\/wjh.v8.i35.1557","journal-title":"World J Hepatol"},{"issue":"2","key":"604_CR153","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","volume":"134","author":"R Moucari","year":"2008","unstructured":"Moucari R, Asselah T, Cazals-Hatem D et al (2008) Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134(2):416\u2013423. https:\/\/doi.org\/10.1053\/j.gastro.2007.11.010","journal-title":"Gastroenterology"},{"key":"604_CR154","doi-asserted-by":"publisher","unstructured":"Nahon P, Bourcier V, Layese R et al (2017) Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152(1):142\u2013156.e2. https:\/\/doi.org\/10.1053\/j.gastro.2016.09.009","DOI":"10.1053\/j.gastro.2016.09.009"},{"issue":"1 Suppl","key":"604_CR155","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.jhep.2014.08.003","volume":"61","author":"F Negro","year":"2014","unstructured":"Negro F (2014) Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 61(1 Suppl):S69\u2013S78. https:\/\/doi.org\/10.1016\/j.jhep.2014.08.003","journal-title":"J Hepatol"},{"issue":"6","key":"604_CR156","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","volume":"149","author":"F Negro","year":"2015","unstructured":"Negro F, Forton D, Crax\u00ec A et al (2015) Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149(6):1345\u20131360. https:\/\/doi.org\/10.1053\/j.gastro.2015.08.035","journal-title":"Gastroenterology"},{"issue":"5","key":"604_CR157","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1128\/JVI.80.5.2418-2428.2006","volume":"80","author":"SU Nielsen","year":"2006","unstructured":"Nielsen SU, Bassendine MF, Burt AD et al (2006) Association between hepatitis C virus and very-low-density lipoprotein (VLDL)\/LDL analyzed in iodixanol density gradients. J Virol 80(5):2418\u20132428. https:\/\/doi.org\/10.1128\/JVI.80.5.2418-2428.2006","journal-title":"J Virol"},{"issue":"7","key":"604_CR158","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/apt.14934","volume":"48","author":"G Novo","year":"2018","unstructured":"Novo G, Macaione F, Giannitrapani L et al (2018) Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study. Aliment Pharmacol Ther 48(7):740\u2013749. https:\/\/doi.org\/10.1111\/apt.14934","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"604_CR159","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13730-016-0244-z","volume":"6","author":"F Obata","year":"2017","unstructured":"Obata F, Murakami T, Miyagi J et al (2017) A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant. CEN Case Rep 6(1):55\u201360. https:\/\/doi.org\/10.1007\/s13730-016-0244-z","journal-title":"CEN Case Rep"},{"issue":"5","key":"604_CR160","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.dld.2018.10.019","volume":"51","author":"V Occhipinti","year":"2018","unstructured":"Occhipinti V, Farina L, Vigan\u00f2 M et al (2018) Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma. Dig Liver Dis 51(5):719\u2013723. https:\/\/doi.org\/10.1016\/j.dld.2018.10.019","journal-title":"Dig Liver Dis"},{"issue":"5","key":"604_CR161","first-page":"471","volume":"11","author":"M Ohsawa","year":"1998","unstructured":"Ohsawa M, Tomita Y, Hashimoto M et al (1998) Hepatitis C viral genome in a subset of primary hepatic lymphomas. Mod Pathol 11(5):471\u2013478","journal-title":"Mod Pathol"},{"issue":"1","key":"604_CR162","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1161\/01.cir.96.1.22","volume":"96","author":"M Okabe","year":"1997","unstructured":"Okabe M, Fukuda K, Arakawa K et al (1997) Chronic variant of myocarditis associated with hepatitis C virus infection. Circulation 96(1):22\u201324. https:\/\/doi.org\/10.1161\/01.cir.96.1.22","journal-title":"Circulation"},{"issue":"37(2)","key":"604_CR06","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4274\/tjh.galenos.2019.2019.0177","volume":"6","author":"M Okay","year":"2020","unstructured":"Okay M, Aslan T, \u00d6zdemir E et al (2020) Splenic marginal zone lymphoma in Turkey: association with hepatitis B instead of hepatitis C virus as an etiologic and possible prognostic factor - A multicenter cohort study. Turk J Haematol 6(37(2)):84\u201390. https:\/\/doi.org\/10.4274\/tjh.galenos.2019.2019.0177","journal-title":"Turk J Haematol"},{"issue":"2","key":"604_CR163","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijcard.2011.07.016","volume":"164","author":"CP Oliveira","year":"2013","unstructured":"Oliveira CP, Kappel CR, Siqueira ER et al (2013) Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol 164(2):221\u2013226. https:\/\/doi.org\/10.1016\/j.ijcard.2011.07.016","journal-title":"Int J Cardiol"},{"issue":"11","key":"604_CR164","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/jvh.12725","volume":"24","author":"O Osibogun","year":"2017","unstructured":"Osibogun O, Ogunmoroti O, Michos ED et al (2017) HIV\/HCV coinfection and the risk of cardiovascular disease: a meta-analysis. J Viral Hepat 24(11):998\u20131004. https:\/\/doi.org\/10.1111\/jvh.12725","journal-title":"J Viral Hepat"},{"key":"604_CR165","doi-asserted-by":"publisher","unstructured":"Pavone P, Tieghi T, d\u2019Ettorre et al (2016) Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect 22(5):462.e1\u2013462.e4623. https:\/\/doi.org\/10.1016\/j.cmi.2015.12.030","DOI":"10.1016\/j.cmi.2015.12.030"},{"issue":"3","key":"604_CR166","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5114\/ceh.2018.78124","volume":"4","author":"A Pellicelli","year":"2018","unstructured":"Pellicelli A, Giannelli V, Zoli V et al (2018) Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma. Clin Exp Hepatol 4(3):197\u2013200. https:\/\/doi.org\/10.5114\/ceh.2018.78124","journal-title":"Clin Exp Hepatol"},{"issue":"10","key":"604_CR167","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2459\/JCM.0000000000000278","volume":"16","author":"A Pepe","year":"2015","unstructured":"Pepe A, Meloni A, Borsellino Z et al (2015) Myocardial fibrosis by late gadolinium enhancement cardiac magnetic resonance and hepatitis C virus infection in thalassemia major patients. J Cardiovasc Med 16(10):689\u2013695. https:\/\/doi.org\/10.2459\/JCM.0000000000000278","journal-title":"J Cardiovasc Med"},{"issue":"3","key":"604_CR168","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2471\/BLT.19.231522","volume":"98","author":"H Perazzo","year":"2020","unstructured":"Perazzo H, Castro R, Luz PM et al (2020) Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis. Bull World Health Organ 98(3):188\u2013197K. https:\/\/doi.org\/10.2471\/BLT.19.231522","journal-title":"Bull World Health Organ"},{"issue":"1","key":"604_CR169","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.atherosclerosis.2014.11.025","volume":"238","author":"M Perticone","year":"2015","unstructured":"Perticone M, Maio R, Tassone EJ et al (2015) Insulin-resistance HCV infection-related affects vascular stiffness in normotensives. Atherosclerosis 238(1):108\u2013112. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.11.025","journal-title":"Atherosclerosis"},{"issue":"5","key":"604_CR170","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.25508","volume":"55","author":"S Petta","year":"2012","unstructured":"Petta S, Torres D, Fazio G et al (2012) Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 55(5):1317\u20131323. https:\/\/doi.org\/10.1002\/hep.25508","journal-title":"Hepatology"},{"issue":"3","key":"604_CR171","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1136\/gutjnl-2013-30610","volume":"63","author":"S Petta","year":"2014","unstructured":"Petta S, Macaluso FS, Crax\u00ec A (2014) Cardiovascular diseases and HCV infection: a simple association or more? Gut 63(3):369\u2013375. https:\/\/doi.org\/10.1136\/gutjnl-2013-30610","journal-title":"Gut"},{"issue":"1","key":"604_CR172","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","volume":"69","author":"S Petta","year":"2018","unstructured":"Petta S, Adinolfi LE, Fracanzani AL et al (2018) Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol 69(1):18\u201324. https:\/\/doi.org\/10.1016\/j.jhep.2018.02.015","journal-title":"J Hepatol"},{"issue":"7","key":"604_CR173","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/leu.2012.29","volume":"26","author":"J Peveling-Oberhag","year":"2012","unstructured":"Peveling-Oberhag J, Crisman G, Schmidt A et al (2012) Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia 26(7):1654\u20131662. https:\/\/doi.org\/10.1038\/leu.2012.29","journal-title":"Leukemia"},{"issue":"1","key":"604_CR174","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jhep.2013.03.018","volume":"59","author":"J Peveling-Oberhag","year":"2013","unstructured":"Peveling-Oberhag J, Arcaini L, Hansmann ML et al (2013) Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 59(1):169\u2013177. https:\/\/doi.org\/10.1016\/j.jhep.2013.03.018","journal-title":"J Hepatol"},{"issue":"7","key":"604_CR175","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jvh.12518","volume":"23","author":"J Peveling-Oberhag","year":"2016","unstructured":"Peveling-Oberhag J, Arcaini L, Bankov K et al (2016) The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat 23(7):536\u2013544. https:\/\/doi.org\/10.1111\/jvh.12518","journal-title":"J Viral Hepat"},{"issue":"9001","key":"604_CR176","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/s0140-6736(96)91328-8","volume":"347","author":"P Pioltelli","year":"1996","unstructured":"Pioltelli P, Zehender G, Monti G et al (1996) HCV and non-Hodgkin lymphoma. Lancet 347(9001):624\u2013625. https:\/\/doi.org\/10.1016\/s0140-6736(96)91328-8","journal-title":"Lancet"},{"issue":"9055","key":"604_CR177","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/s0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (London, England) 349(9055):825\u2013832. https:\/\/doi.org\/10.1016\/s0140-6736(96)07642-8","journal-title":"Lancet (London, England)"},{"issue":"1","key":"604_CR178","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-2000-9258","volume":"20","author":"T Poynard","year":"2000","unstructured":"Poynard T, Ratziu V, Benmanov Y et al (2000) Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 20(1):47\u201355. https:\/\/doi.org\/10.1055\/s-2000-9258","journal-title":"Semin Liver Dis"},{"key":"604_CR179","doi-asserted-by":"publisher","unstructured":"Pozzato G, Mazzaro C, Artemova M et al (2020) Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.17036","DOI":"10.1111\/bjh.17036"},{"issue":"13","key":"604_CR180","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1182\/blood.v98.13.3745","volume":"98","author":"ER Quinn","year":"2001","unstructured":"Quinn ER, Chan CH, Hadlock KG et al (2001) The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 98(13):3745\u20133749. https:\/\/doi.org\/10.1182\/blood.v98.13.3745","journal-title":"Blood"},{"issue":"2","key":"604_CR181","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/hon.2575","volume":"37","author":"S Rattotti","year":"2019","unstructured":"Rattotti S, Ferretti VV, Rusconi C et al (2019) Lymphomas associated with chronic hepatitis C virus infection: a prospective multicenter cohort study from the rete Ematologica Lombarda (REL) clinical network. Hematol Oncol 37(2):160\u2013167. https:\/\/doi.org\/10.1002\/hon.2575","journal-title":"Hematol Oncol"},{"issue":"6","key":"604_CR182","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.gastrohep.2019.02.002","volume":"42","author":"T Revuelto Artigas","year":"2019","unstructured":"Revuelto Artigas T, Betriu Bars \u00c0, Zaragoza Velasco N et al (2019a) Antiviral treatment does not improve subclinical atheromatosis in patients with chronic hepatitis caused by hepatitis C virus. El tratamiento antiviral no mejora la ateromatosis subcl\u00ednica en pacientes con hepatitis cr\u00f3nica por virus de la hepatitis C. Gastroenterol Hepatol 42(6):362\u2013371. https:\/\/doi.org\/10.1016\/j.gastrohep.2019.02.002","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"604_CR183","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.rce.2018.12.007","volume":"219","author":"T Revuelto Artigas","year":"2019","unstructured":"Revuelto Artigas T, Zaragoza Velasco N, G\u00f3mez Arbones X et al (2019b) Chronic hepatitis C infection: An independent risk factor for subclinical atheromatosis. Infecci\u00f3n cr\u00f3nica por el virus de la hepatitis C: un factor de riesgo independiente para la ateromatosis subcl\u00ednica. Rev Clin Esp 219(6):293\u2013302. https:\/\/doi.org\/10.1016\/j.rce.2018.12.007","journal-title":"Rev Clin Esp"},{"issue":"4(1)","key":"604_CR07","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-018-0009-4","volume":"2","author":"D Roccatello","year":"2018","unstructured":"Roccatello D, Saadoun D, Ramos-Casals M et al (2018) Cryoglobulinaemia. Nat Rev Dis Primers 2(4(1)):11. https:\/\/doi.org\/10.1038\/s41572-018-0009-4","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"604_CR184","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/jvh.12843","volume":"25","author":"E Rodr\u00edguez de Santiago","year":"2018","unstructured":"Rodr\u00edguez de Santiago E, Vel\u00e1zquez Kennedy K, Garc\u00eda Gonz\u00e1lez M et al (2018) HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: the game is not over after HCV eradication. J Viral Hepat 25(5):614\u2013615. https:\/\/doi.org\/10.1111\/jvh.12843","journal-title":"J Viral Hepat"},{"issue":"12","key":"604_CR185","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/1744666X.2018.1538790","volume":"14","author":"C Romano","year":"2018","unstructured":"Romano C, Cuomo G, Ferrara R et al (2018) Uncommon immune-mediated extrahepatic manifestations of HCV infection. Expert Rev Clin Immunol 14(12):1089\u20131099. https:\/\/doi.org\/10.1080\/1744666X.2018.1538790","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"604_CR186","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jhep.2014.09.031","volume":"62","author":"R Rossotti","year":"2015","unstructured":"Rossotti R, Travi G, Pazzi A et al (2015) Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3\/NS4A inhibitor-based treatment. A case report. J Hepatol 62(1):234\u2013237. https:\/\/doi.org\/10.1016\/j.jhep.2014.09.031","journal-title":"J Hepatol"},{"issue":"5","key":"604_CR187","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2012-202770","volume":"73","author":"D Saadoun","year":"2014","unstructured":"Saadoun D, Resche Rigon M, Thibault V et al (2014) Peg-IFN\u03b1\/ribavirin\/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 73(5):831\u2013837. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202770","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"604_CR188","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jhep.2014.08.015","volume":"62","author":"D Saadoun","year":"2015","unstructured":"Saadoun D, Resche Rigon M, Pol S et al (2015) PegIFN\u03b1\/ribavirin\/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 62(1):24\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2014.08.015","journal-title":"J Hepatol"},{"key":"604_CR189","doi-asserted-by":"publisher","unstructured":"Saadoun D, Pol S, Ferfar Y, et al (2017) Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology 153(1):49\u201352.e5. https:\/\/doi.org\/10.1053\/j.gastro.2017.03.006","DOI":"10.1053\/j.gastro.2017.03.006"},{"key":"604_CR190","doi-asserted-by":"publisher","unstructured":"Sagnelli E, Pisaturo M, Stanzione M et al (2013) Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 11(9):1174\u20131180.e11. https:\/\/doi.org\/10.1016\/j.cgh.2013.03.025","DOI":"10.1016\/j.cgh.2013.03.025"},{"key":"604_CR191","doi-asserted-by":"publisher","unstructured":"Sagnelli E, Macera M, Russo A et al (2019) Epidemiological and etiological variations in hepatocellular carcinoma. Infection. https:\/\/doi.org\/10.1007\/s15010-019-01345-y","DOI":"10.1007\/s15010-019-01345-y"},{"key":"604_CR192","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1017\/S0950268819002012","volume":"148","author":"C Sagnelli","year":"2020","unstructured":"Sagnelli C, Uberti-Foppa C, Cella E et al (2020) Molecular epidemiology of HIV-1 infection in immigrant population in norther Italy. Epidemiol Infect 148:e19. https:\/\/doi.org\/10.1017\/S0950268819002012","journal-title":"Epidemiol Infect"},{"issue":"5","key":"604_CR193","first-page":"RA55","volume":"14","author":"MJ Sanchez","year":"2008","unstructured":"Sanchez MJ, Bergasa NV (2008) Hepatitis C associated cardiomyopathy: potential pathogenic mechanisms and clinical implications. Med Sci Monit 14(5):RA55\u2013RA63","journal-title":"Med Sci Monit"},{"issue":"9","key":"604_CR194","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1086\/507640","volume":"43","author":"T Santantonio","year":"2006","unstructured":"Santantonio T, Medda E, Ferrari C et al (2006) Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 43(9):1154\u20131159. https:\/\/doi.org\/10.1086\/507640","journal-title":"Clin Infect Dis"},{"issue":"7","key":"604_CR195","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1128\/JVI.06956-11","volume":"86","author":"MA Sarhan","year":"2018","unstructured":"Sarhan MA, Pham TN, Chen AY et al (2018) Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol 86(7):3723\u20133735. https:\/\/doi.org\/10.1128\/JVI.06956-11","journal-title":"J Virol"},{"issue":"12","key":"604_CR196","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/jvh.12746","volume":"24","author":"A Schiavinato","year":"2017","unstructured":"Schiavinato A, Zanetto A, Pantano G et al (2017) Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. J Viral Hepat 24(12):1168\u20131176. https:\/\/doi.org\/10.1111\/jvh.12746","journal-title":"J Viral Hepat"},{"issue":"4","key":"604_CR197","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/00004836-200104000-00023","volume":"32","author":"MY Shapira","year":"2001","unstructured":"Shapira MY, Muszkat M, Braunstein I et al (2001) Co-occurrence of hepatocellular carcinoma and lymphoma in patients with hepatitis C virus cirrhosis. J Clin Gastroenterol 32(4):368\u2013369. https:\/\/doi.org\/10.1097\/00004836-200104000-00023","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"604_CR08","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.18632\/oncotarget.23138","volume":"9","author":"J Shimono","year":"2017","unstructured":"Shimono J, Miyoshi H, Kato T et al (2017) Hepatitis C virus infection is an independent prognostic factor in follicular lymphoma. Oncotarget 9(2):1717\u20131725. https:\/\/doi.org\/10.18632\/oncotarget.23138","journal-title":"Oncotarget"},{"issue":"4","key":"604_CR198","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3350\/cmh.2016.0087","volume":"23","author":"HP Shin","year":"2017","unstructured":"Shin HP, Park JA, Burman B et al (2017) Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. Clin Mol Hepatol 23(4):316\u2013322. https:\/\/doi.org\/10.3350\/cmh.2016.0087","journal-title":"Clin Mol Hepatol"},{"key":"604_CR199","doi-asserted-by":"publisher","unstructured":"Sigon G, D\u2019Ambrosio R, Clerici M et al (2019) Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. Liver Int. https:\/\/doi.org\/10.1111\/liv.14213","DOI":"10.1111\/liv.14213"},{"issue":"11","key":"604_CR200","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.2337\/dc06-0456","volume":"29","author":"R Sim\u00f3","year":"2006","unstructured":"Sim\u00f3 R, Lecube A, Genesc\u00e0 J et al (2006) Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 29(11):2462\u20132466. https:\/\/doi.org\/10.2337\/dc06-0456","journal-title":"Diabetes Care"},{"issue":"2","key":"604_CR201","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/hep.28297","volume":"63","author":"ME Sise","year":"2016","unstructured":"Sise ME, Bloom AK, Wisocky J et al (2016) Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 63(2):408\u2013417. https:\/\/doi.org\/10.1002\/hep.28297","journal-title":"Hepatology"},{"issue":"1","key":"604_CR202","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.kint.2019.04.030","volume":"97","author":"ME Sise","year":"2020","unstructured":"Sise ME, Chute DF, Oppong Y et al (2020) Direct-acting antiviral therapy slows kidney function decline in patients with hepatitis C virus infection and chronic kidney disease. Kidney Int 97(1):193\u2013201. https:\/\/doi.org\/10.1016\/j.kint.2019.04.030","journal-title":"Kidney Int"},{"issue":"1","key":"604_CR203","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12879-018-3278-3","volume":"18","author":"C Soeiro","year":"2018","unstructured":"Soeiro C, Gon\u00e7alves C, Marques et al (2018) Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir\/Ledipasvir in HCV\/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study. BMC Infect Dis 18(1):364. https:\/\/doi.org\/10.1186\/s12879-018-3278-3","journal-title":"BMC Infect Dis"},{"issue":"6","key":"604_CR204","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/hep.28137","volume":"63","author":"V Soriano","year":"2016","unstructured":"Soriano V, Barreiro P, de Mendoza C (2016) Hypoglycemia in a diabetic patient during hepatitis C therapy. Hepatology 63(6):2065\u20132066. https:\/\/doi.org\/10.1002\/hep.28137","journal-title":"Hepatology"},{"issue":"2","key":"604_CR205","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5604\/16652681.1231581","volume":"16","author":"JG Stine","year":"2017","unstructured":"Stine JG, Wynter JA, Niccum B et al (2017) Effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis C. Ann Hepatol 16(2):215\u2013220. https:\/\/doi.org\/10.5604\/16652681.1231581","journal-title":"Ann Hepatol"},{"key":"604_CR206","doi-asserted-by":"publisher","unstructured":"Stroffolini T, Sagnelli E, Sagnelli C et al (2018) Geographical pattern of chronic liver diseases in Italy: results from two pooled national surveys Eur J Intern Med. pii: S0953\u20136205(18)30408\u20134. https:\/\/doi.org\/10.1016\/j.ejim.2018.10.015","DOI":"10.1016\/j.ejim.2018.10.015"},{"issue":"3","key":"604_CR207","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/apt.15101","volume":"49","author":"TH Su","year":"2019","unstructured":"Su TH, Liu CJ, Tseng TC et al (2019) Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. Aliment Pharmacol Ther 49(3):331\u2013339. https:\/\/doi.org\/10.1111\/apt.15101","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"604_CR208","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1182\/blood-2005-09-3679","volume":"107","author":"F Suarez","year":"2006","unstructured":"Suarez F, Lortholary O, Hermine O et al (2006) Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 107(8):3034\u20133044. https:\/\/doi.org\/10.1182\/blood-2005-09-3679","journal-title":"Blood"},{"issue":"15","key":"604_CR209","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2014-12-618652","volume":"125","author":"P Sultanik","year":"2015","unstructured":"Sultanik P, Klotz C, Brault P et al (2015) Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood 125(15):2446\u20132447. https:\/\/doi.org\/10.1182\/blood-2014-12-618652","journal-title":"Blood"},{"issue":"2","key":"604_CR210","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1872-034X.2008.00439.x","volume":"39","author":"S Tada","year":"2009","unstructured":"Tada S, Saito H, Ebinuma H et al (2009) Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism. Hepatol Res 39(2):195\u2013199. https:\/\/doi.org\/10.1111\/j.1872-034X.2008.00439.x","journal-title":"Hepatol Res"},{"issue":"2","key":"604_CR211","doi-asserted-by":"publisher","first-page":"e0192627","DOI":"10.1371\/journal.pone.0192627","volume":"13","author":"L Taramasso","year":"2018","unstructured":"Taramasso L, Di Biagio A, Bovis F et al (2018) Trend of estimated glomerular filtration rate during ombistasvir\/paritaprevir\/ritonavir plus dasabuvir \u00b1 ribavirin in HIV\/HCV co-infected patients. PLoS One 13(2):e0192627. https:\/\/doi.org\/10.1371\/journal.pone.0192627","journal-title":"PLoS One"},{"issue":"6","key":"604_CR212","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jhep.2007.01.021","volume":"46","author":"G Targher","year":"2007","unstructured":"Targher G, Bertolini L, Padovani R et al (2007) Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 46(6):1126\u20131132. https:\/\/doi.org\/10.1016\/j.jhep.2007.01.021","journal-title":"J Hepatol"},{"key":"604_CR213","doi-asserted-by":"crossref","unstructured":"Teegen EM, D\u00fcrr M, Maurer MM et al (2019) Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: therapy of HCV-recurrence. Transpl Infect Dis 21","DOI":"10.1111\/tid.13020"},{"issue":"2","key":"604_CR214","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.amjcard.2012.09.028","volume":"111","author":"B Terrier","year":"2013","unstructured":"Terrier B, Karras A, Cluzel P et al (2013) Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis. Am J Cardiol 111(2):265\u2013272. https:\/\/doi.org\/10.1016\/j.amjcard.2012.09.028","journal-title":"Am J Cardiol"},{"issue":"2","key":"604_CR215","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/s0021-9150(02)00388-x","volume":"166","author":"H Tomiyama","year":"2003","unstructured":"Tomiyama H, Arai T, Hirose K et al (2003) Hepatitis C virus seropositivity, but not hepatitis B virus carrier or seropositivity, associated with increased pulse wave velocity. Atherosclerosis 166(2):401\u2013403. https:\/\/doi.org\/10.1016\/s0021-9150(02)00388-x","journal-title":"Atherosclerosis"},{"issue":"1","key":"604_CR216","doi-asserted-by":"publisher","first-page":"S302","DOI":"10.1016\/s0168-8278(17)30921-2","volume":"66","author":"TT Tran","year":"2017","unstructured":"Tran TT, Mehta D, Goldstein A et al (2017) Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: results from clinical trials of ombitasvir\/paritaprevir\/ritonavir and dasabuvir \u00b1 ribavirin. J Hepatol 66(1):S302. https:\/\/doi.org\/10.1016\/s0168-8278(17)30921-2","journal-title":"J Hepatol"},{"issue":"4","key":"604_CR217","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40121-018-0218-x","volume":"7","author":"TT Tran","year":"2018","unstructured":"Tran TT, Mehta D, Mensa F et al (2018) Pan-genotypic hepatitis C treatment with Glecaprevir and Pibrentasvir for 8 weeks resulted in improved cardiovascular and metabolic outcomes and stable renal function: a post-hoc analysis of phase 3 clinical trials. Infect Dis Ther 7(4):473\u2013484. https:\/\/doi.org\/10.1007\/s40121-018-0218-x","journal-title":"Infect Dis Ther"},{"key":"604_CR218","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijcard.2014.11.200","volume":"181","author":"MS Tsai","year":"2015","unstructured":"Tsai MS, Hsu YC, Yu PC et al (2015) Long-term risk of acute coronary syndrome in hepatitis C virus infected patients without antiviral treatment: a cohort study from an endemic area. Int J Cardiol 181:27\u201329. https:\/\/doi.org\/10.1016\/j.ijcard.2014.11.200","journal-title":"Int J Cardiol"},{"issue":"5","key":"604_CR219","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cardfail.2008.12.003","volume":"15","author":"JI Tsui","year":"2009","unstructured":"Tsui JI, Whooley MA, Monto A et al (2009) Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the heart and soul study. J Card Fail 15(5):451\u2013456. https:\/\/doi.org\/10.1016\/j.cardfail.2008.12.003","journal-title":"J Card Fail"},{"issue":"6","key":"604_CR220","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1590\/0074-0276140090","volume":"109","author":"AC Urbaczek","year":"2014","unstructured":"Urbaczek AC, Ribeiro LCDEA, Ximenes VF et al (2014) Inflammatory response of endothelial cells to hepatitis C virus recombinant envelope glycoprotein 2 protein exposure. Mem Inst Oswaldo Cruz 109(6):748\u2013756. https:\/\/doi.org\/10.1590\/0074-0276140090","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"11","key":"604_CR221","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1007\/s00595-009-3966-0","volume":"39","author":"T Utsunomiya","year":"2009","unstructured":"Utsunomiya T, Okamoto M, Tsujita E et al (2009) Hepatocellular carcinoma infiltrated with non-Hodgkin\u2019s lymphoma: report of a case. Surg Today 39(11):1010\u20131012. https:\/\/doi.org\/10.1007\/s00595-009-3966-0","journal-title":"Surg Today"},{"issue":"2","key":"604_CR222","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.dld.2015.10.016","volume":"48","author":"E Vanni","year":"2016","unstructured":"Vanni E, Bugianesi E, Saracco G (2016) Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality? Dig Liver Dis 48(2):105\u2013111. https:\/\/doi.org\/10.1016\/j.dld.2015.10.016","journal-title":"Dig Liver Dis"},{"issue":"5","key":"604_CR223","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/hrt.2003.018937","volume":"90","author":"C Vassalle","year":"2004","unstructured":"Vassalle C, Masini S, Bianchi F et al (2004) Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 90(5):565\u2013566. https:\/\/doi.org\/10.1136\/hrt.2003.018937","journal-title":"Heart"},{"issue":"Suppl 2","key":"604_CR224","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3851\/IMP3248","volume":"23","author":"C Vassalle","year":"2018","unstructured":"Vassalle C, Petta S, Pepe A et al (2018) Expert opinion on managing chronic HCV in patients with cardiovascular disease. Antivir Ther 23(Suppl 2):35\u201346. https:\/\/doi.org\/10.3851\/IMP3248","journal-title":"Antivir Ther"},{"issue":"32","key":"604_CR225","doi-asserted-by":"publisher","first-page":"11054","DOI":"10.3748\/wjg.v20.i32.11054","volume":"20","author":"C Visco","year":"2014","unstructured":"Visco C, Finotto S (2014) Hepatitis C virus and diffuse large B-cell lymphoma: pathogenesis, behavior and treatment. World J Gastroenterol 20(32):11054\u201311061. https:\/\/doi.org\/10.3748\/wjg.v20.i32.11054","journal-title":"World J Gastroenterol"},{"issue":"11","key":"604_CR226","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/bjc.2017.345","volume":"117","author":"C Visco","year":"2017","unstructured":"Visco C, Wang J, Tisi MC et al (2017) Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. Br J Cancer 117(11):1685\u20131688. https:\/\/doi.org\/10.1038\/bjc.2017.345","journal-title":"Br J Cancer"},{"issue":"2","key":"604_CR227","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/aje\/kwm061","volume":"166","author":"CS Wang","year":"2007","unstructured":"Wang CS, Wang ST, Yao WJ et al (2007) Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol 166(2):196\u2013203. https:\/\/doi.org\/10.1093\/aje\/kwm061","journal-title":"Am J Epidemiol"},{"issue":"15","key":"604_CR228","doi-asserted-by":"publisher","first-page":"8122","DOI":"10.1128\/JVI.00125-07","volume":"81","author":"G Waris","year":"2007","unstructured":"Waris G, Felmlee DJ, Negro F et al (2007) Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 81(15):8122\u20138130. https:\/\/doi.org\/10.1128\/JVI.00125-07","journal-title":"J Virol"},{"issue":"9973","key":"604_CR229","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","volume":"385","author":"DP Webster","year":"2015","unstructured":"Webster DP, Klenerman P, Dusheiko GM (2015) Hepatitis C. Lancet 385(9973):1124\u20131135. https:\/\/doi.org\/10.1016\/S0140-6736(14)62401-6","journal-title":"Lancet"},{"issue":"3","key":"604_CR230","doi-asserted-by":"publisher","first-page":"281","DOI":"10.15403\/jgld.2014.1121.273.daa","volume":"27","author":"P Weidner","year":"2018","unstructured":"Weidner P, Boettche D, Zimmerer T et al (2018) Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C. J Gastrointestin Liver Dis 27(3):281\u2013289. https:\/\/doi.org\/10.15403\/jgld.2014.1121.273.daa","journal-title":"J Gastrointestin Liver Dis"},{"issue":"1","key":"604_CR231","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/jrpp.JRPP_19_110","volume":"9","author":"AH Wong","year":"2020","unstructured":"Wong AH, Sie J, Chen A et al (2020) Glycemic control after initiating direct-acting antiviral agents in patients with hepatitis C virus and type 2 diabetes mellitus using the United States integrated healthcare system. J Res Pharm Pract 9(1):16\u201323. https:\/\/doi.org\/10.4103\/jrpp.JRPP_19_110","journal-title":"J Res Pharm Pract"},{"issue":"6","key":"604_CR232","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/apt.12234","volume":"37","author":"ZM Younossi","year":"2013","unstructured":"Younossi ZM, Stepanova M, Nader F et al (2013) Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther 37(6):647\u2013652. https:\/\/doi.org\/10.1111\/apt.12234","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"604_CR233","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/jvh.12448","volume":"22","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Elsheikh E, Stepanova M et al (2015) Ledipasvir\/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels. J Viral Hepat 22(12):977\u2013982. https:\/\/doi.org\/10.1111\/jvh.12448","journal-title":"J Viral Hepat"},{"issue":"1","key":"604_CR234","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jhep.2015.08.027","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Estep M et al (2016) Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. J Hepatol 64(1):29\u201336. https:\/\/doi.org\/10.1016\/j.jhep.2015.08.027","journal-title":"J Hepatol"},{"issue":"2","key":"604_CR235","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1189\/jlb.0106014","volume":"80","author":"LJ Zhao","year":"2006","unstructured":"Zhao LJ, Zhang XL, Zhao P et al (2006) Up-regulation of ERK and p38 MAPK signaling pathways by hepatitis C virus E2 envelope protein in human T lymphoma cell line. J Leukoc Biol 80(2):424\u2013432. https:\/\/doi.org\/10.1189\/jlb.0106014","journal-title":"J Leukoc Biol"},{"issue":"11","key":"604_CR09","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014755","volume":"98","author":"X Zhu","year":"2019","unstructured":"Zhu X, Jing L, Li X (2019) Hepatitis C virus infection is a risk factor for non-Hodgkin lymphoma: a MOOSE-compliant meta-analysis. Medicine (Baltimore) 98(11):e14755. https:\/\/doi.org\/10.1097\/MD.0000000000014755","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"604_CR236","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s007050050100","volume":"142","author":"AL Zignego","year":"1997","unstructured":"Zignego AL, Ferri C, Giannini C et al (1997) Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin\u2019s lymphoma: evidence for a pathogenetic role. Arch Virol 142(3):545\u2013555. https:\/\/doi.org\/10.1007\/s007050050100","journal-title":"Arch Virol"},{"issue":"2","key":"604_CR237","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.510310230","volume":"31","author":"AL Zignego","year":"2000","unstructured":"Zignego AL, Giannelli F, Marrocchi ME et al (2000) T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 31(2):474\u2013479. https:\/\/doi.org\/10.1002\/hep.510310230","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"604_CR238","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/s1590-8658(07)80009-0","volume":"39","author":"AL Zignego","year":"2007","unstructured":"Zignego AL, Giannini C, Monti M et al (2007) Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis 39(Suppl 1):S38\u2013S45. https:\/\/doi.org\/10.1016\/s1590-8658(07)80009-0","journal-title":"Dig Liver Dis"}],"container-title":["Advances in Experimental Medicine and Biology","Advances in Microbiology, Infectious Diseases and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2020_604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T17:14:38Z","timestamp":1618247678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/5584_2020_604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030712013","9783030712020"],"references-count":247,"URL":"https:\/\/doi.org\/10.1007\/5584_2020_604","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"17 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}